Gilead Sciences
GILD · NASDAQ · USD · Healthcare
Price
+15.6% since 20/07/20263 months · High $160.51 (-4.6%) · Low $126.90
What is happening
Gilead Sciences has fallen 5% since its 6-week high on 15/10/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayHow deep is the dip?
- from the 6-week high-4.6%
Highest daily price: $160.51 on 15/10/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-4.6%
Highest price in 52 weeks: $160.51 (Yahoo)
Marking places no order – it only helps you keep track.
Catalysts
2 h ago- News, last 10 days
- no recent news
- Next earnings
- 29/10/2026 · in 9 days
- Last report
- 04/08/2026 +6.9% vs estimate
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Headquarters:
- Foster City, United States
- 52-week range:
- $114.02 – $160.51
- Website:
- gilead.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
